Definium Therapeutics, Inc. (DFTX) Earnings Call Transcript
February 26, 2026
Earnings Call Speaker Segments
Thanks, operator, and good afternoon to all of you. We appreciate you being here with us today as we walk through Definium's Full Year 2025 Financial Results and Business Updates. Rob Barrow, our Chief Executive Officer, is going to lead today's call, and he's joined by Dr. Daniel Karlin, our Chief Medical Officer, Brandi Roberts, our Chief Financial Officer, and Matt Wiley, our Chief Commercial Officer. A replay of today's conference call, both as an audio recording and a webcast, will be accessible online too, and the press release announcement for this call lays out those details. On today's call, we'll be making certain forward-looking statements, which include, without limitation, statements regarding the potential safety, efficacy, and regulatory and clinical progress of our product candidates, our anticipated cash runway, and our future expectations, plans, partnerships, and prospects. A variety of risks could affect these statements, for instance changes in market conditions and difficulties tied to research and development and regulatory approval processes; these risk factors, along with others, are set out in the filings made with the SEC and applicable Canadian securities regulators, including our annual report on Form 10-K filed today. The assumptions, opinions, and estimates of management at the date such statements are made form the basis for forward-looking statements, including the non-occurrence of the risks and uncertainties described in the filings made with the SEC and the applicable Canadian securities regulators or other significant events occurring outside of Definium's normal course of business. Please be cautioned not to put undue reliance on these forward-looking statements, which are made as of today, February 26th, 2026. Definium disclaims any obligation to update such statements, even if management's views change, except as required by law; with that, let me turn the call over to Rob.
Appreciate that, Gita. And I want to thank everyone for joining us on today's call. We're feeling a great deal of enthusiasm here as we prepare to deliver the updates we have for you today, especially since the key data readouts we've long been waiting for on lysergide tartrate, also known as DT120 ODT, in generalized anxiety disorder and major depressive disorder are now just a matter of months away. The momentum is palpable, both inside our development programs and throughout the psychiatry field, as we brace for psychedelics to become accepted as potentially game-changing new therapeutic choices. Our confidence in DT120 ODT's promise as a best-in-class product candidate remains as strong as ever. Over this past year, our team set the standard once more when it comes to scientific rigor, efficiency, and thoughtful execution. Reflecting on 2025, there's no way I could feel more pride in our team and in what we've achieved. Throughout the year, we advanced our late-stage pipeline at a rapid pace, substantially strengthened our balance sheet, and continued expanding both our world-class leadership team and our board of directors to drive the next stage of our growth. By staying in close contact with the FDA through the Breakthrough Therapy Designation process, we reached agreement on many critical aspects of our development and submission plan. That positions us to submit our NDA for DT120 ODT as fast and efficiently as possible, provided the trials later this year produce positive results. Our commercial planning and organizational preparedness have matched those R&D gains, helped by bringing in key commercial leadership under Matt Wiley, who joined as chief commercial officer in March 2025. We've seen strong engagement across the board, which prepares us to fulfill our goal of once more setting the benchmark for excellence in how psychedelics are adopted. The start of 2026 brought the introduction of Definium Therapeutics — a new identity that captures the way our organization has grown and the leading role we hold in psychiatry. Built on careful execution, strict science, and a bold sense of what we can achieve, our distinct approach puts us in position to create treatments that scale and remain within reach, while generating lasting worth for those who hold our stock. Three phase III results should arrive during 2026, with the earliest only a matter of months off, and we see the coming year as decisive — for Definium as well as the field of psychiatry as a whole. We have one clear objective: to meet the pressing demand for a novel category of medications capable of bringing real benefit to the millions of individuals dealing with GAD and MDD—conditions that for too long have lacked adequate options, given existing treatments' heavy burden, only moderate effectiveness, and frequently poor tolerability. With the foundation of our successful dose optimization phase IIb trial, which appeared in JAMA last September, our DT120 ODT clinical program is made up of four pivotal phase III trials: two focused on GAD—Voyage and Panorama—and two focused on MDD—Emerge and Ascend. I'm happy to report today that Emerge, the first of our pivotal MDD studies, has completed enrollment, and we expect to report top-line data in late Q2. Emerge may be the last of our three pivotal trials to kick off, but we're genuinely excited that it's the first readout we get to present from our phase III efforts. Doing things in this order gives us an opportunity to generate data in another significant market indication, and it also allows us to engage with FDA while we still have ample time to explore options for potentially accelerating our regulatory filing approach in MDD and GAD. On top of that, we've made solid headway in launching Ascend, the second pivotal trial of ours in MDD. The first sites for Ascend are now activated, and we expect the first participant to be dosed by early Q2. Turning to our GAD program, enrollment continues to look strong in both Voyage and Panorama. Voyage is roughly 80% enrolled, and given the rate at which patients are enrolling and the current queue, we expect to wrap up enrollment within the next few weeks, with top-line data anticipated in early Q3. I am glad to report as well that the pre-planned blinded sample size re-estimation has finished, and no increase in sample size was needed. Dan is going to give more specifics about that sample size re-estimation shortly. Enrollment for Panorama, which is our second phase III trial in GAD, is moving along at a fast pace, and we remain on track to report top-line results in the latter half of 2026. When we hold our Investor and Analyst Day in April, we plan to share a further update on enrollment as well as disclose the outcome of Panorama's blinded sample size re-estimation. Our team stays committed to producing high-quality data throughout our phase III studies, aimed at two of the biggest and most impactful indications in psychiatry; we keep believing in the best-in-class potential of DT120 ODT and remain devoted to the scientific rigor and disciplined execution that have characterized our organization and its successes so far; with that, I will hand the call to Dan so he can share more details about our clinical programs.
Thanks, Rob. The enrollment patterns we're observing throughout our phase III GAD and MDD trials continue to leave us very optimistic. Our sites and investigators have been receiving a great deal of our time. As the moment when we deliver top-line data draws nearer, there's a strong sense of enthusiasm and involvement. As Rob said, we're particularly eager to bring out Emerge as our initial pivotal readout in late Q2. Our phase II Montgomery-Åsberg Depression Rating Scale, or MADRS, findings in GAD gave us considerable clinical assurance as we designed and executed Emerge, yet never before have we had the chance to prove DT120's efficacy in a committed MDD population made up of patients in a major depressive episode. GAD and MDD overlap substantially as disorders, but MDD is classified as an episodic condition involving stretches of dysthymia or normal mood, broken up by major depressive episodes, and those episodes feature dysthymia or depressed mood that has to last no less than two weeks and can continue for many months. A more uninterrupted state of elevated anxiety is what characterizes and defines GAD. In our GAD program, beginning at phase IIb, we showed DT120's extraordinary capacity to ease this ongoing background condition, whereas our MDD program aims to show the identical impact on how major depressive episodes run their course. Considered together, these findings indicate that, should it win approval, DT120 could become a data-driven, evidence-based clinical option for providers and patients, with the possibility of bettering patient outcomes, regardless of whether the patient is presently in a major depressive episode. Two parts make up each of our four pivotal studies spanning GAD and MDD. Part A is a 12-week randomized, double-blind, placebo-controlled, parallel group period that evaluates the safety and efficacy of one dose of DT120 ODT against placebo, and part B is a 40-week extension period offering chances for open label treatment. In our MDD studies, the primary endpoint is the change from baseline in MADRS score at week six comparing DT120 ODT 100 µg with placebo. The MDD trials were built with 80% power to identify a five-point improvement over placebo on this endpoint. For our GAD studies, the primary endpoint is the change from baseline in the Hamilton Anxiety Scale, or HAM-A, at week 12 comparing DT120 ODT 100 µg with placebo. The GAD trials were designed to carry 90% power for detecting a five-point improvement over placebo on this endpoint. Our phase III studies take after our successful phase IIb study, where we saw placebo-adjusted improvements of 7.7 points on the HAM-A and 6.4 points on the MADRS at week 12. Given how other approved pharmacotherapies have usually demonstrated a placebo-adjusted effect of under four points on these endpoints, we think DT120 could potentially be not just a best-in-class product among psychedelics, but among anxiolytics and antidepressants at large. Though placebo-adjusted changes matter critically for proving efficacy, the absolute magnitude of improvement might better capture the real-world patient experience. DT120 really distinguished itself here, showing a 21.9 point absolute drop in HAM-A scores by week 12, which lined up with a 48% clinical remission rate and a 65% response rate; when it came to comorbid depressive symptoms, we observed an 18.7 point absolute reduction in MADRS scores at week 12. Now let me walk through where things stand with our MDD studies. Enrollment has wrapped up, and we anticipate top-line data from Emerge arriving in late Q2. Given how Emerge has progressed, we're proceeding with launching our second pivotal MDD study, Ascend. For Ascend, our enrollment target sits at roughly 175 participants, randomized two to one to two, receiving DT120 ODT 100 µg, 50 µg, or placebo. The first sites for Ascend are now activated, and dosing should kick off by early Q2. We anticipate that Ascend will keep gaining from the operational efficiencies that made Emerge's enrollment so swift, such as the capacity to fast-track certain sites that took part in Emerge along with those currently enrolling in our GAD program. Turning to our GAD program, Voyage is now in the last phases of enrollment, with completion expected within the next few weeks. For Voyage, we're aiming to enroll about 200 participants, randomized one to one to DT120 ODT 100 µg or placebo, whereas for Panorama, our enrollment target is 250 participants, randomized two to one to two to DT120 ODT 100 µg, 50 µg, or placebo. Every GAD study incorporates a sample size re-estimation, which permits adjusting the target enrollment through a blinded assessment of nuisance parameters. As Rob noted earlier, we finished the sample size re-estimation for Voyage and concluded that the trial's sample size does not need to grow. When we first calculated study power, we assumed a standard deviation of 10 points and a non-evaluable rate of 15% at week 12. Looking at the first 100 participants who made it through week 12, we found a model-based standard deviation of 6.7 points on the HAM-A and a non-evaluable rate of 10%. What these observations indicate is that the study's capacity to identify a statistically significant drug effect goes well beyond the planned power. In fact, should those nuisance parameters stay the same through the final analysis, that would mean the study carries over 99% power for detecting a five-point difference on the HAM-A, and the smallest difference needed to reach statistical significance would come in under two points. Outside of DT120, we're thrilled to have kicked off our phase II study of DT-402 in autism spectrum disorder, or ASD, in late 2025. DT-402, the R-enantiomer of MDMA, has demonstrated encouraging prosocial effects alongside a potentially favorable tolerability profile. We're advancing DT-402 to go after the core symptoms of ASD, particularly tackling social communication, which sits at the heart of the disorder's experience. This program, we believe, offers yet another meaningful treatment opportunity, considering the substantial unmet need, ASD's rising prevalence, and the absence of FDA-approved therapies that directly target these core symptoms. Once we wrapped up a phase I single ascending dose trial that mapped out how well DT-402 was tolerated along with its pharmacokinetics and pharmacodynamics in healthy adult volunteers, we went ahead and gave the first dose to a participant in our phase IIa study, with initial data anticipated later this year. This trial uses a single-dose, open label design and looks at early efficacy signals in as many as 20 adults who have ASD. The objectives and endpoints of this study were built to capture the pharmacodynamics and clinical effects of DT-402 spanning multiple functional domains. Throughout our late-stage pipeline, we're seeing solid momentum and getting close, fast, to a number of pivotal readouts for our DT120 ODT program. In our view, the standout profile of DT120 could make it best in class among GAD and MDD pharmacotherapies, and we have confidence in our strategy and execution to generate the widest possible impact for the millions of patients who need it. I'll hand things over to Matt for commercial remarks on DT120.
Appreciate that, Dan. Our whole organization remains firmly dedicated to, and intently concentrated on, achieving flawless commercial readiness for the possible launches in GAD and MDD. Throughout the last 12 months, we have exhaustively charted the nationwide provider landscape, and working hand in hand with our cross-functional internal groups, we have ranked the key states for launch. Should approval come, we stand entirely ready to move swiftly and accurately. When it comes to commercializing Definium, our aim is to provide a truly high-touch, white-glove experience for the providers we serve — one that carries forward the collaborative, partnership-driven style that has set us apart across our clinical development work and with our trial sites. That approach has served as a crucial point of differentiation for us, and we plan to make it a cornerstone of our commercial model; we recognize completely that providers will have needs spanning many dimensions, well past simply receiving product information; they will want straightforward direction regarding REMS certification, regulatory obligations, operational integration, and reimbursement pathways. Because of that, we are putting in place the strong infrastructure and cross-functional teams needed to handle all of these areas smoothly and to assist providers beginning on day one. To bolster our launch capabilities, we have brought together an outstanding commercial leadership team during the last 12 months across marketing, market access, and operations. This leadership group brings extensive experience in steering complicated launches, encompassing work with REMS and scheduled drugs. Their demonstrated history of success gives us enormous confidence as we get ready for launch; we are eager to share further specifics about our commercialization strategy during our upcoming Analyst Day on April 22nd. Zooming out, our message is straightforward: We are getting ready to bring forward something substantially different. In the past, whenever new classes of medicines have arrived in psychiatry, they have created considerable value and produced multi-billion dollar opportunities. We think DT 120 could not only take part in that sort of opportunity, but also surpass what has come before — above all, for patients who desperately need more than better. With that, I will hand our call to Brandi so she can go over our full year 2025 results. Brandi?
Thanks, Matt. When we look at the twelve months ended December 31, 2025, R&D spending reached $117.7 million. A year earlier, for the period ending December 31, 2024, that figure stood at $65.3 million. So we're talking about an increase of $52.4 million. Several things drove that. DT120 program costs were higher by $44.7 million. Internal personnel costs rose $9.3 million, reflecting broader research and development capabilities. Preclinical and other program expenses added $0.4 million. Partially offsetting those gains, DT-402 program expenses declined by $2 million. G&A came in at $48.6 million for the year ended December 31st, 2025. That compares with $38.6 million for the year ended December 31st, 2024, so an increase of $10 million. The main drivers of that increase were $6 million tied to professional services and pre-commercialization activities, $3.6 million in personnel-related expenses that support our expanded operational activities, $0.7 million in directors deferred share unit expense related to our stock price appreciation year over year, and $0.5 million in other administrative expenses, partially offset by a $0.8 million decline in legal and patent related expenses. Looking at the full picture, our spending on R&D and G&A during 2025 came in right where we had projected, while we continued to make meaningful strides on both the DT120 and DT-402 programs. For the year ending December 31st, 2025, we recorded a net loss of $183.8 million, compared with $108.7 million for the year ending December 31st, 2024. Keep in mind that fluctuations in the fair value of our 2022 USD Financing Warrants can have a major effect on our net loss. In 2025, that fair value change totaled $22.8 million, driven by our stock price rising from $6.96 on December 31st, 2024, to $13.39 on December 31st, 2025. We closed out 2025 with $411.6 million in cash equivalents and investments, compared with $273.7 million at the end of 2024. Based on the operating plan we have now and the milestones we expect to hit, we think the cash equivalents and investments we held as of December 31st, 2025 will carry us through funding operations into 2028. It's exciting to head into 2026 with the kind of financial flexibility that lets us move faster on a number of important efforts, such as NDA preparation, market access, priority activities, market research, and KOL education. The goal behind this spending is to bolster our path to market and, should DT120 ODT win approval, make possible a commercial launch that is both well-prepared and robust. Another positive sign is how our shareholder mix keeps maturing — current owners are staying highly involved, and we're seeing more curiosity from newcomers as 2025 unfolds. Looking toward 2026, which will be a pivotal stretch for us, we're staying committed to running the business with discipline, allocating capital carefully, and moving our programs forward in a manner that builds value over the long haul. At this point I'll hand things back to Rob for his closing comments.
Appreciate that, Brandi. The past year, 2025, brought daring goals together with careful follow-through, and now in 2026, Definium stands ready to release several of the most significant findings in psychiatry, which showcases how far we've come and our drive to deliver innovative, widely scalable treatments to people whom current care options fail to serve well. Thanks to a solid balance sheet and a late stage pipeline carrying numerous catalysts over the coming months, we're eager to keep building value for our shareholders along with the millions of patients who are entitled to something beyond merely better. Naturally, we could not have achieved any of this without our outstanding team, whose enthusiasm, dedication, and peerless execution keep raising the bar for everyone in our industry. Once more, we appreciate your presence on today's call. At this point, we'll take questions from the line.
Hi there, good afternoon. I appreciate the updates, and thanks for fielding my question. Regarding this interim analysis you carried out, it's quite compelling for Voyage. I'm wondering, in a hypothetical case where the DMC were to request or suggest that you increase the size of the trial, what would the placebo-adjusted delta have needed to be, roughly speaking, for that to occur? And just to verify, with this interim, were there no additional scenarios, like halting for futility or perhaps halting for success? Thank you.
Okay, thank you very much for that question, Andrew. To start with, this was a sample size re-estimation performed in a blinded manner. A key aspect of this analysis is that the study is never unblinded by us. No inferential testing gets performed, so we truly do not gain any knowledge regarding how the two groups performed, whether separately or relative to each other. In effect, you can view it as examining the right-hand portion, just past the plus or minus, of the 95% confidence interval in order to evaluate the standard error and confirm that the assumptions established when the study began are being mirrored, or that we aren't losing power owing to incorrect assumptions. Nothing can be inferred, and no learnings can be taken, from either this analysis or from any other result of it. We are definitely pleased to find that our assumptions are holding up well. If anything, as Dan said on this call, we have power that is certainly sufficient at 99% or higher should the present variables, at least those parameters, continue. We are looking forward to reaching study results and finally conducting that inferential test and examining how DT120 performs compared with placebo.
Wow. Alright, thanks. Just very briefly — once you've got the Voyage data in the top line by early Q3, might you think about releasing some of the part B open label extension data in pieces, purely to demonstrate even more how long-lasting a single 120 dose can be? If not, at what point would you disclose the open label portion? Thanks.
Yes, definitely. So, one key area where our attention has really been centered is, naturally, how well the effect holds up and what the response trends look like across a full 12 months. Naturally, every one of the trials has been underway for a good while at this point. As we keep gathering patients who've reached particular milestones—whether that's retreatment events or completing a set period of time—we'll naturally wind up with more data and greater assurance in that data, which lets us share some observations. We haven't locked in any pledge about the precise timing for presenting part B data; we definitely don't want to jump the gun by presenting data we don't consider representative or lack confidence in at any given moment. We'll definitely be examining that, and as those data accumulate—whether through any of the readouts from the studies still running or at some other point—we'll get a chance to share as many observations as we can regarding how part A and part B performed.
Great. Makes sense. Thanks again.
Good afternoon. Marc isn't available, so Basma is speaking instead. Thanks for taking what we wanted to ask. The first thing we want to ask concerns the interim look. Once more, has the interim look for Panorama been carried out by you folks yet, or is that still pending? Or do you intend to perform it after reaching 80% enrollment, the way Voyage was handled? And about MDD, at what point exactly do you expect the interim look to happen for the Emerge trial? Then our second thing relates to the GAD readouts. In terms of the remission rate, what do you anticipate? What figure would strike you as a solid and differentiated one compared with the standard of care? Thanks; that covers what we had.
Thank you very much, Basma. Regarding the interim analysis for Voyage, naturally, we made that announcement earlier today. When it comes to Panorama, which is our second pivotal trial in GAD, we will provide further information along with updates on enrollment during our Analyst Day in April. As for the two MDD studies, Emerge has, of course, reached full enrollment at this point, and the data — the top-line data we intend to present — will be the completed final top-line analysis from that trial. At present, we are not performing an interim look on either of the MDD studies, as was the plan. On the topic of GAD and the remission rate, I'll hand things over to Dan so he can perhaps weigh in on how we think about response patterns and, in the end, what shapes patient experience and value within these populations.
That's a wonderful question regarding the rate of remission, since we have, of course, discussed this based on what came out of our phase IIb trials. One thing worth emphasizing is that the majority of our knowledge concerning remission rates brought on by pharmacotherapy derives from MDD research. When it comes to MDD, what we observe with an SRI — which, as you know, serves as the first-line option and is the treatment used most often — is an attributable remission rate in real-world settings falling somewhere between 10% and 30%. Naturally, interpreting such data isn't straightforward, given that MDD is by nature a cyclical condition, meaning that once a major depressive episode has resolved, whether through medication or not, that interval represents a period of remission from those symptoms. We made certain design decisions in phase III for GAD as well as MDD, namely aiming open-label treatments — that is, the part B treatments — at the threshold separating mild from moderate illness on the scale, so the HAM-A and the MADRS. What we're truly examining in this instance is whether, given that open-label treatment is available in the part Bs, we can reliably treat patients down into that mild or better range through redosing. Although we aren't specifying a priori what we'd hope to see in terms of an absolute remission rate, our intention here is to move people out of moderate or worse illness and determine how effectively we can maintain them at mild or better.
Thank you.
Hello, Evie here, covering for Gavin. Congrats on everything you've accomplished over this year. It's wonderful to see the SSRE finished at this point. Could you share any color regarding enrollment and where it stands for the second GAD and MDD trial, given that Voyage data is now anticipated by early 3Q? For our second question, beyond the SSRE and variability, is there anything else you can point to that adds incremental confidence? That might be something along the lines of baseline characteristics or rollover retention, screen failures, or similar items. Thank you.
Yeah, thank you so much for asking that. Regarding where we stand with enrollment — naturally, for Emerge, which is our initial MDD trial, it's now completely enrolled, and we expect the data in late Q2. We've simply been blown away by the speed at which we managed to fill that study, and by how thrilled we believe the field is, along with the investigators involved in this trial, about what's possible here — we certainly share that excitement, and our team has executed on these trials incredibly well. On Voyage, we mentioned roughly 80% enrollment, and we keep witnessing remarkably robust enrollment, with our strongest months so far. We're definitely observing ongoing growth and faster enrollment throughout the program; as for our second trial, Panorama, well, once again, we'll provide additional updates during our Analyst Day in April — we've felt encouraged on every front and are genuinely pleased with our enrollment position in that trial. With Ascend, we'll be kicking off within the next few weeks. We're truly eager to get trials up and running more quickly than we'd even expected. Being able to have trials DEA activated and DEA approvals secured in only a handful of weeks has let us genuinely speed up the launch of that second MDD trial. Honestly, on all fronts, enrollment trends have been very encouraging, and that puts us in a strong spot for three crucial readouts during this year. As for experimental confidence, we won't discuss particular variables or what we're observing in them. Our confidence in the DT120 profile is extraordinary. As Dan said in his prepared remarks, given the observed parameters from the interim analysis for Voyage, that would suggest a rather high — above 99% — power to detect a five-point difference, with fewer than two points needed for separation between the groups to reach a statistically positive result, provided those nuisance variables remain the same at the study's end as they were at the interim analysis. That provides us considerable confidence if, you know, a trial only needs to demonstrate a couple points of difference for a statistically positive outcome. Naturally, we'd prefer to see something better than that; we believe a four-point difference between the arms is what we'd truly like to observe; that would genuinely distinguish itself as the best drug we've seen, the best results in GAD so far. We're definitely eager to deliver that data. Everything we're observing across all the trials keeps giving us confidence in the program and sets us up really well for these readouts later in the year.
Thank you.
Hi there, good afternoon everyone. I appreciate you giving me the chance to ask a couple of things. Nice work on everything so far — I'm excited about what should be a really eventful year full of data. I have 2 questions. First off, I believe enrollment schedules shifted somewhat relative to what you'd previously guided, and that happened in both directions. What I'd like to know is how that affects your thinking about the number of potential patients out there dealing with each of these conditions who might have interest in a psychedelic. Then, regarding the interim analysis passing, plus the clearly low variability and the dropouts, my impression is that even quite a tight delta might reach statistical significance in Voyage. Could you share a bit more about where you currently stand on what counts as a clinically meaningful delta? And really, if you do achieve stat sig on a smaller delta, what might that mean for your strategy in Panorama, and how would you expect the drug to be positioned from a commercial standpoint? Thank you.
Right. Brian, thank you very much, and those are two excellent questions. I'll hand things over to Dan for the first one. Dan, perhaps you could share your thoughts on how we approach these patient groups, and also how, naturally, these individuals appear in studies and come to receive clinical care.
Yeah, that's a great question, and you've made a good observation. The shifts in timing don't really alter our view of the patient population, but what we do know is that in today's psychiatric landscape, with the medications that are out there right now, MDD has drawn both drug development efforts and clinical attention for roughly the past 30 years, which left GAD somewhat behind, with no new therapies approved for GAD since 2007. The truth is that these two conditions share a hugely overlapping patient group, and although GAD tends to be a more persistent, background kind of condition—something people experience daily, often for a large portion of their lives—that very fact can stop people from seeking treatment. They've grown accustomed to how they are, even when it's fairly disruptive to their lives. It isn't an abrupt shift that people notice happening to them the way they do when a major depressive episode begins, which is frequently what pushes people to get care. We're genuinely thrilled about the chance to potentially offer a medication here that works no matter what prompts someone to seek treatment—whether it's that ongoing anxious state, anxiety that has newly emerged, or the start of a major depressive episode, which is a true change in state for them. Our thinking is that whatever drives the presentation, we plan to deliver a body of evidence showing DT120 would be a strong option for the patient. That affords us some flexibility in timing, for people over the course of their lives and over the course of their illness.
Appreciate that, Dan. Brian, regarding your follow-up on what counts as clinically meaningful — that's another excellent one, and honestly it matters a lot for context, both when it comes to that gap and when it comes to how big the overall change is. There are definitely many different ways people approach these ideas. From where we sit — Dan touched on this briefly during the prepared remarks — in the real world, patients obviously aren't receiving placebo. We certainly aim to show as big a placebo-adjusted response as possible, but seeing an absolute magnitude of change that clearly stands apart from the other available options — sure, comparing across trials and so on always comes with caveats, yet we believe that's a key variable to keep an eye on too. As for that placebo-adjusted change, once again, when it's drugs we think could be transformative, our view is that ought to show up in how consistently patients experience the benefit and how big that benefit is versus a placebo. Sure, we're quite encouraged when the clinical bar is low compared with where we began and where we powered the study, but we'd absolutely want to see a change that stands out and keeps standing out the way it did in phase II. In GAD, looking at the currently approved therapies out there, none of them reliably delivers at or above a 4-point delta over placebo in those trials. If the magnitude of change we observe is as big as that or bigger, and the placebo-adjusted change exceeds four points, it's tough for us not to feel tremendously excited. We don't draw any sort of bright line around these kinds of concepts, but we're very much after data that impress and data that get us — and we believe payers, providers, everyone — enthusiastic about the potential, since we truly believe it's there and hope the data holds up in support of that.
Thank you.
Hello, and I appreciate you fielding these. There are plenty of intriguing inquiries, and plenty of intriguing responses as well. I was simply curious — you brought up that four-point threshold, which, as you know, isn't a strict cutoff or anything like that, but it's something you've referenced regarding the GAD side. Could you remind us, given that MDD will now come first, could you essentially perform that same kind of review regarding what you'd hope to observe and set it against what has been observed for MDD? Perhaps also remind everyone what was previously observed on the MADRS side in the earlier study, and maybe some caveats surrounding, you know, what was observed, since that study wasn't necessarily designed for that purpose initially.
Absolutely, and thank you for that question, Franc. Once more, as we examine the field of products that have received approval along with those still being developed, the research we've conducted so far keeps giving us reasons for optimism on a qualitative level. Dan brought up what we're observing within the GAD population, with, as you know, less severe forms of the illness. I believe our attention really centers heavily on how severe both MDD and GAD are, since those severity levels reflect the impact on patients and can account for a great deal of the burden as well as the value. As we consider the response, we consider severity along with that overall size of change, and that is, once again, where we observed truly striking outcomes across both sets of symptoms — for anxiety symptoms and for depression symptoms. In MADRS scores, we observed a 6.4 point gap separating 120 and placebo. My sense is that this began from a lower baseline than what we'd anticipate in a dedicated MDD population whose patients are in a major depressive episode. I think we will definitely be presenting that picture more thoroughly by the time we reach the Analyst Day in April. I think as we draw nearer and nearer to the readouts, we want to establish complete context for those expectations, and simply for the realities of that landscape. When we examine that at present, once more, observing an effect — one adjusted for placebo — that exceeds four points appears rather significant, and observing a double-digit absolute magnitude of change likewise appears rather significant in our view. That holds particularly within the MDD population, where moving patients from severe depression symptoms to high, moderate, or more severe would not, in our view, amount to a major change. As we consider this readout, we once again want to observe a large absolute magnitude of change, and a change adjusted for placebo that is as large as the drug is capable of producing.
All right. Perhaps I could slip in one final question here. Regarding the situation, whenever you look into this matter, a lot of remarks come up about how, when moving from a phase II trial to a phase III trial, it's completely typical for the placebo difference to shrink. Does that ring true for folks? Is there some rationale for it, or is it simply a way of hedging a bit?
No, not really. What I'd say is that in the history of psychiatric research, you do sometimes find studies where that compression shows up. But there are cases — and we've observed this with schizophrenia, and in several other situations too — where certain therapies that perform the best keep avoiding that kind of narrowing as they move further along in development. Things like adjustments to the design or to operations can influence this, and that's exactly why our phase III approach has us so optimistic. We built our phase II program so that it was run and structured precisely the way a phase III trial would be, even though we felt it was absolutely essential to pin down a dose response and pick the right dose to carry into the pivotal trials — that's the reason we conducted phase II the way we did. Because of that, the operational tweaks we made from phase II to phase III were tiny. Essentially, we're repeating the very same exercise, except it involves two or three arms rather than the five arms we used in phase II. So once again, that leaves us feeling very confident. On top of that, there are several elements of the trial design that we believe will promote stronger patient retention and get us to the primary endpoint of these trials. Dan brought up the fact that in the interim analysis for Voyage, the non-evaluable rate came in at 10%. If you set that beside the figure of more than 25% from our phase II data, well, we believe that difference is mostly explained by part B, the nine-month extension, where patients can get open-label 120 provided they make it through the entire 12-week blinded control period. All these elements leave us quite confident about how these trials are being operationalized, and quite confident as we get closer to the data.
Great stuff. Thank you.
Hello there, and good afternoon. It's great to witness the advancement. We appreciate you fielding our inquiries. To start, I'm simply interested in your perspective on a possible submission approach, assuming both GAD phase III trials turn out favorably and the initial phase III MDD trial, Emerge, also succeeds. Would you finish 2 MDD trials prior to submitting an sNDA, or does some rationale exist for holding off until the 2nd trial?
Yes, and many thanks for asking that, Pete. It would be too soon to address submission approach in detail, since we haven't got the data yet. Naturally, we believe that when data is stronger, a sponsor is able to present a more persuasive case, and that holds universally. We'll examine the data extremely carefully, and should we observe a striking outcome — in terms of both placebo-adjusted and absolute change magnitude, something that truly energizes us — then we will definitely pursue those discussions to find the most effective route ahead for the 2 indications.
All right. And then, regarding the earlier-stage asset you brought up, 402 — could you share a bit more detail on how you evaluate clinical effect? Which scales matter most to you? Both in your deck and in today's PR, functional biomarkers get a mention. Could you expand on that?
Sure. I'll hand that question to Dan for his thoughts.
Yes, I'm glad to address that, and I appreciate the question about 402. Of course, given how much buzz there is around 120 at times, we rarely get the opportunity to discuss this as often as we'd prefer, since we're genuinely enthusiastic about this program. We've completed a single ascending dose safety study, and that provides us with solid data for dosing under a single dose paradigm, which is precisely what we stated we had done — namely, advance the drug in a single dose open label paradigm. How to measure things in ASD is always a fascinating matter. You're inquiring about the scales, the Vineland, and other scales that prior approval attempts have employed, naturally, given that no drugs have been approved for the core symptoms of this disorder. What constitutes the right measure at the right moment is still quite an open discussion, both within the field among experts who treat people with ASD and with regulators, who are keen to approve drugs for this condition, which truly lacks treatments aimed at its core symptoms. In the present early signal of efficacy study, what we're examining are measures possessing high granularity. We're after measures with high sensitivity and high granularity, so that we can measure repeatedly across a dosing day to observe change consistent with the drug's expected PK and PD. We haven't discussed precisely which measures we're employing, but we are using components of established measures together with some novel approaches to social interaction, social communication, and the other domains where we believe the drug will prove effective. We're considering measurement right from the start and giving a great deal of thought to measurement techniques capable of tracking alongside the drug through its development phases and, ultimately, through to regulatory submission, should we reach that point, and possibly even measures that might accompany the drug out into the world, if approved.
All right, and congratulations again.
Hello, everyone. Appreciate you taking my question, and nice work on the progress. My question is about MDD. One thing we keep hearing regarding SPRAVATO is that it helps with PRD symptoms, yet it doesn't do as much for boosting general day-to-day productivity — say, your output at work, as one illustration. I realize you're tracking several quality of life measures in Emerge, though what really interests me is the WPAI. Would you mind elaborating on what you expect there, and could you share any big-picture commentary on how these patients are faring past mere MDD symptom relief? I've got another one coming after this.
Yes. Appreciate it, Chris. I'll hand things to Dan for the WPAI discussion. Let me start by noting that given the dosing schedule involved — needing to visit a clinic for several hours, either multiple times or at minimum once weekly over a lengthy period — obviously, showing up at work is definitely something that influences productivity. A therapy requiring only infrequent visits — assuming we can demonstrate the same durability observed in studies thus far — is certainly, in our view, something that would set DT120 apart from every other option available globally today, and that would be a fairly significant effect, correct? Going to the doctor's office once or twice per week is a considerable hardship. Even past the productivity you can actually measure, being present at work and managing to do so will be a key factor. We'd also expect this to surface in patient satisfaction and in how much the drug gets used overall. I'll let Dan go into more detail on the WPAI.
Right. So the areas the WPAI examines are absenteeism — missing work — and presenteeism — being at work but not functioning fully — and it attempts to gauge a general impairment percentage during work hours. Naturally, this isn't a primary endpoint, and we aren't setting out to prove efficacy in a broad sense using an instrument of this kind. As you noted, I believe this matters a great deal, correct? Simply because someone reports fewer symptoms, or symptoms that are suppressed, that doesn't automatically translate into that person being capable again of doing what they need and wish to do in life. We're strongly aligned with the notion that, just as phase II showed, the lived experience of participants following treatment — since, naturally, in contrast to SPRAVATO, whose treatment involves an ongoing intermittent regimen, we expect extended stretches of time separating treatments, assuming such retreatment is even required at all. How people characterized what they went through after treatment in phase II was less about, as you're suggesting, a kind of symptom suppression, and more about a perspective that had shifted regarding the future in GAD. Clearly, as we're hoping to observe in MDD, this pertains to the anhedonic aspect, or the inability to derive pleasure from activities that would ordinarily bring someone enjoyment. The reason we assess the WPAI along with additional measures of functioning and life participation is precisely that: we stay optimistic and hopeful that the transformation we observe with DT120 reflects a more complete, whole-person change toward a condition one might term recovery.
Thanks. That's quite useful. I just have one brief item. In these trials, are you gathering data on time to patient time to discharge? And if that's the case, are you observing anything, you know, that might point to any changes away from that monitoring window of six to eight hours?
Yes, that's an excellent question. We definitely are gathering data at high granularity. In our view it's critically important to have arguments driven by data and an understanding driven by data of what occurs on a dosing day, and to ultimately characterize that so it can inform regulatory discussions. We begin assessing — we have a structured set of assessments that we measure each hour beginning at hour five. Naturally we observe every patient no matter the dose or whether they get placebo through hour eight in the study. Ultimately, we expect to have, you know, once again, a high granularity assessment across the different domains and ultimately the time at which patients can be discharged safely, we believe, from a treatment session; naturally, since we have a number of open label treatment sessions, we have some insights there, which we cannot share just yet in great detail. We want, once again, to aggregate enough data to feel confident in sharing that prior to doing so. Certainly as we move forward and as we reach a top line readout, we believe it's really important, given the nature of these drugs, to begin characterizing that, something we've been doing with a really thoughtful approach starting with our phase II study and something being refined and giving us increasing confidence as we've gotten through the conduct of our phase III program.
Thanks.
Hello, Arabella here, filling in for Patrick. We really appreciate you fielding this, and congratulations on everything you've accomplished. We can't wait for the readouts that are coming. Given that Panorama has sites in Europe as well, might there be notable variations in how diagnosis is done, how patients respond to placebo, or the usual treatment approach that could bring in extra variability?
Sure, I'll hand that over to Dan.
That's a great question, and you've made a solid observation. European sites are indeed part of the Panorama study. As you point out, regional differences exist in psychiatric practice — even across the United States, practice patterns vary between different parts of the country. The diagnostic criteria themselves stay constant, but how they get applied may differ from one location to another. Our approach to navigating that is to be extremely specific in our protocols. Of course, the diagnostic criteria we rely on are standard across every country and every site. Application of those criteria is standardized, and oversight and monitoring of that standardization happens above the site level. All of our participants undergo what is genuinely a three-part confirmatory set of assessments, and just one of those parts draws on the site assessment. We have central diagnostic confirmation along with central severity confirmation, which removes that sort of site variability. There's another benefit for the patient population: since we take both — for GAD, which, as you know, includes the European sites, and for MDD, which doesn't, because we don't base enrollment in our studies on some particular set of prior treatments or on having failed some particular set of prior treatments — variation in local treatment patterns won't influence who gets brought into the trial. We have tremendous confidence that, across the sites here in the States and the sites in Europe, we're enrolling the participants we set out to enroll. And because we're studying this as a monotherapy, of course, the participants we get are independent of whatever local practice patterns might exist for treating these disorders.
Thanks a lot. That was fast. I realize we've covered this ground already, but I want to zero in on GAD. I understand it's early days still. If results from both Voyage and Panorama come back positive, does that clear the path to a filing? Or are there other pieces, like longer-term safety information, that could stand in the way of an NDA submission?
Certainly, it's too soon to give a definitive answer on our filing strategy and the mechanics of filing before we sit down with FDA for a pre-NDA meeting and reach a final conclusion. Given how constructive our conversations with FDA have been all the way through our pivotal programs, we're quite optimistic that part A data, with durability data extending to 12 weeks, is sufficient for filing. Once we have top line data from these studies, we've already got extensive efforts underway so that we're prepared to file as fast as we can and, once again, aim to establish that benchmark for just how efficient and speedy we can be in crossing the finish line.
Great, thanks a lot.
Hello, and good afternoon. I appreciate you taking my question, and congratulations on the progress. My question was about—actually, I have two. First, regarding the MDD program: you mentioned the study has 80% power to detect a five-point change, while in your GAD study using MADRS you observed a 6.4-point change. What I'd like to grasp is, from a commercial standpoint, to reach a meaningful share of the MDD market—not merely those patients who are treatment resistant—what kind of profile would you want to see? Second, when you consider the regulatory environment and how it's evolving, plus the FDA's recent position favoring a single-trial requirement, do you believe two studies are still necessary for each of the two indications, or might there be a chance to look at fewer studies if the studies this year perhaps come out positive? Thank you.
Okay, thank you very much, Ami. I might go through those in the opposite sequence and invite Matt and/or Dan to weigh in on the first one you raised. When it comes to the regulatory position, the legal criteria governing drug approvals have existed for a long time now. It's really heartening for us to observe some of the conversation regarding streamlined routes, regulatory comprehension, and adaptability, even though we will keep holding ourselves to the strictest benchmarks of scientific discipline. That said, these indications overlap heavily, and naturally we are observing and quantifying anxiety symptoms and depression symptoms throughout all 4 trials. When you pull together a substantial collection of evidence, if consistent findings appear across several studies, across several domains, with a strong level of both standalone and placebo-adjusted change, then the better the data look, the more compelling the case becomes, whether that involves 1, 2, or additional studies, for any program. We will absolutely factor all of that in and, based on how strong and how large the responses are that we observe across these trials, be able to map out a regulatory route ahead. On the first item, once more, I believe it's somewhat early to speak with too much precision about segmentation and about precisely where this would fit in, you know, in a commercial context. I'll hand it to Matt so he can perhaps comment on how we think about that, plus the kinds of expectations and hopes we would have for both commercial uptake and for reimbursement and similar matters.
Thanks, Rob, and I appreciate the question. So when it comes to the patient profile in MDD, let me first pull back and consider both of these indications. These indications are highly prevalent. In the United States, there are more than 50 million patients across both indications. A very significant unmet need still exists. When we do market research with HCPs, what we find is that across both indications, the unmet need exceeds 70%. Even with the care available to them today, the treatment paradigms still leave something significantly lacking. As we know, payers do manage drugs, and branded drugs entering the market usually face a step or two, which we believe can slightly narrow the overall addressable market. For both GAD and MDD, there are a significant number of patients who, if approved, are going to benefit from DT120.
Got it. I appreciate the response. Thank you.
Good afternoon, and thank you for fielding our questions while we wait with great anticipation for all the results you've said will be coming out during this year. There are two things I'd like to ask about: one relates to how products get developed, and the other concerns the business side. To start with a conceptual point, it seems to us that the investment community may be applying a stricter threshold to psychedelic medicines when it comes to separation of points on rating scales used in trials, and maybe that isn't entirely fair. For quite a while, our position has been that the place where the standard genuinely ought to be set differently is the standard of care around how long a treatment's effects last. From where you sit, does that strike you as an accurate description of the real world? The reason I bring this up is that, in the response you gave earlier regarding the clinical meaningfulness of a statistical figure on HAM-A, and maybe to an even greater degree on MADRS, I don't believe I caught any direct mention of durability.
Yeah. No. I really appreciate that, Sumant. Whenever durability comes to mind, two things are involved: the pragmatic constraints on how far out in time one can examine the durability of a single dose under placebo-controlled conditions. Beyond that, there are definitely things we can learn through the way we run our trials. We'll be examining how response patterns emerge and how long it ultimately takes for events to occur, looking past a span of just 12 weeks. You know, if you survey the landscape, 12 weeks represents the farthest limit that the majority of trials go, especially for medications that don't need a lengthy period. Take SRIs, for example — they may require numerous weeks before any kind of effect appears; so naturally, a sponsor running those trials would extend far past that point in order to achieve that separation. As for durability, in the conversations we've had with regulators so far, being able to demonstrate it at 12 weeks following one single intervention is essentially at, or very near, the maximum standard anyone could possibly establish for a medication. Part of what shaped our choices when designing the phase III program was placing our primary endpoint B at that particular point in time, which, if these trials succeed, would let us show what is truly the longest-lasting response we could ever hope for, or could ever hope to have confirmed, within a parallel-group phase of the trial. That characteristic makes it stand apart from every one of the product candidates currently in late-stage development, certainly within our own area. We completely concur that durability matters, and that durability extending past a handful of weeks following one treatment, or, you know, the final treatment or medication, is genuinely significant — which is exactly why we built our trials the way we did.
Understood. Yes, the reason I brought it up is precisely that, since up to now you've demonstrated quite solid durability. Regarding the commercial aspect, Matt, you brought up what you called a "high touch white glove experience." What's your current thinking around pricing in MDD and GAD, at least measured against SPRAVATO for TRD, assuming that remains a solid reference point? How much of that high touch white glove experience could insurers cover?
Excellent question. Yes. Many thanks, Sumant. Yes. Let me just note quickly, and then I'll hand things to Matt. My view is that at this point, when it comes to pricing, speaking in specific terms about pricing is truly premature. As for the dynamics, we keep holding to this growing conviction that the inability of therapies available today to help a patient's depression or anything else isn't a sound proxy for defining a population. What we also observe across a great deal of our HEO R work is that severity acts as an enormous driver of disease burden. That shouldn't come as a shock. The reality that drugs which perform not especially well in a population have failed in that population doesn't imply that people poorly served by those therapies are necessarily worse off. Although we grasp the dynamics of probably not serving as a first line therapy for everybody, we do regard those distinctions as somewhat artificial, and consequently, it's something we can both examine within our subpopulations in our studies, yet wouldn't exactly avoid using things such as SPRAVATO as a comparator, given how artificial that distinction is. I'll hand it to Matt for additional comment on this.
Sumant, when we consider the high touch, or white glove, style of approach we're taking for this launch, the goal is truly to eliminate whatever friction might arise for a patient or a provider. That means a hub service model that's very clear about the reimbursement pathway — how to bill and code, and so forth — plus making sure that what the patient pays out of pocket doesn't become a barrier. Essentially, we want to take away anything standing in the way of getting to therapy as fast as we can. That's our ambition; that's what we're working toward, whether it comes through our field team and high touch field team exposure to HCPs or otherwise within market access, and making sure we have a seamless hub model that genuinely assists in coordinating all the various touch points so the patient experience stays positive.
Thanks.
Once more, I want to express appreciation to all of you for being with us on today's call; we're very enthusiastic about reaching our initial top line readout for Emerge within the coming months. Since we have 3 readouts in total over the span of this year, we view this as truly a pivotal year for our company and are enormously eager to arrive at those data readouts. Thanks once more for being here today, and I hope you'll be with us at our events coming up in April and after that.
Everyone, that wraps up the call for today. We appreciate you joining us, and you're free to hang up at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Definium Therapeutics, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Definium Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.